The novel tyrosine kinase inhibitor ponatinib (iclusig® ) provides new hope for CML patients following previous therapy failure
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Hematology |
| MU Faculty or unit | |
| Citation | |
| Description | Chronic myeloid leukemia is a potentially fatal disease. First-generation and second-generation TKIs provided major advances in therapy, but a proportion of these patients require other treatment options. Ponatinib was developed to fulfll this need, and it has proven to be highly effective in patients where the second-generation TKIs nilotinib and dasatinib fail. The beneft-to-risk ratio for ponatinib is high, although there is an increased risk of vascular occlusive events. Patient monitoring with active management of modifable risk factors (e.g. hypertension, lipids), and decreasing the dose once optimal response is achieved is recommended. Stem-cell transplantation still remains a curative option to be considered, but morbidity and mortality are high. |